Skip to main content
Premium Trial:

Request an Annual Quote

Abcodia, VolitionRx Collaborate on Nucleosome-based Dx for Cancer

NEW YORK (GenomeWeb News) – Abcodia today said that it will collaborate with Singapore-based VolitionRx on developing biomarker-based tests for a variety of cancers.

The London-based firm said that the partnership will discover and develop diagnostic tests for lung, colorectal, and pancreatic cancer using VolitionRx's nucleosome technology. Abcodia said that it will work with VolitonRx on designing the program and identifying cohort samples from its large prospective serum biobank.

"Access to Abcodia's samples will potentially expedite the development of our blood-based diagnostic technology, Nucleosomics," VolitonRx CEO Cameron Reynolds said in a statement. "We believe that data from validation of thousands of samples, across multiple cancer areas, will help us to reach our goal of applying for European CE Mark approval this year."

Further terms of the alliance were not disclosed.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.